ovariectomy ͉ osteoporosis ͉ tumor necrosis factor ͉ sex steroids
strogen deficiency causes osteoporosis, a major source of morbidity and disability in the occidental world (1) . Genotropic and nongenotropic effects of estrogen lead to preservation of bone mass through modulation of bone cell lifespan (2) and decreased cytokine-driven osteoclastogenesis (3) . Among the factors that up-regulate osteoclast formation in estroprevic humans and rodents is tumor necrosis factor ␣ (TNF), a cytokine known to augment the production and the activity of the osteoclastogenic molecule RANKL (4, 5) , and to potently induce IL-1, IL-6, and macrophage colony-stimulating factor, estrogenregulated cytokines known to mediate the bone loss induced by ovariectomy (ovx) (5) . Enhanced T cell production of TNF resulting from increased T cell number in the bone marrow (BM) is known to occur and to be necessary for the increase in osteoclast and the bone waste induced by ovx (6, 7) . The mechanism by which ovx expands the pool of BM T cells is, however, unknown.
To address this issue we investigated the effect of estrogen deficiency on generation and death of cytokine-producing T cells. Our in vivo studies reveal that estrogen deficiency increases T cell activation-induced proliferation, and suppresses apoptosis of active T cells, through IFN-␥-mediated induction of the multitarget immune modulator class II transactivator (CIITA), in antigen (Ag)-presenting cells (APC) and T lymphocytes.
Methods
Mice and Surgery. All animal procedures were approved by the Institutional Animal Care and Use Committee. In all studies, female mice were sham operated or ovariectomized (ovx) at 12 weeks of age as described (8) . Except for APC assays and studies with transgenic mice, C57BL͞6 wild-type (WT) animals were used (Taconic, Germantown, NY). DO11.10 mice (BALB͞c background) were injected i.p. with 10 mg of ovalbumin and 250 l of complete Freund's adjuvant, as described (9) , at surgery and 15 days later. BALB͞c mice, DO11.10 (BALB͞c), IFN-␥ receptor-deficient (IFN-␥R Ϫ/Ϫ ) mice and their WT littermates (129͞sv) were obtained from The Jackson Laboratory.
Cell Purification. Spleen, lymph node, and BM T cells (CD90ϩ and CD4 ϩ ), splenic B cells (CD19ϩ), and BM macrophages (M) (CD11bϩ) were purified by immunomagnetic positive selection. Lymph node dendritic cells (DC) were purified by immunomagnetic negative selection of CD19ϩ, CD90ϩ, and CD11bϩ cells. Peritoneal M were prepared by injection of 3% thioglycolate (1.5 ml per mouse), 5 days before death and retrieval (10) . In each experimental group cells were purified from pools derived from at least five mice 4 weeks after surgery.
APC Assay and MHC Class II (MHCII) Expression.
To test APC activity, we measured proliferation of target T cells from DO11.10 mice, prepared as follows: splenocytes from 10-week-old DO11.10 transgenic BALB͞c mice were cultured in presence of ovalbumin (500 mg͞ml); after 3 days, cells were passed and stimulated with IL-2 (40 units͞ml) for 4 days, washed, and rested for 3 days. Sensitized and purified T cells were then incubated with APCs to be tested. Unfractionated spleen cells, purified B cells, DC, and M prepared from sham-operated or ovx WT BALB͞c mice 2 weeks after surgery were irradiated (2,000 ␥-rad), seeded in 96-well plates (5 ϫ 10 5 cells per 200 l per well) with DO11.10 T cells (APC͞T cells ratio 10:1) in RPMI medium 1640 supplemented with 10% FBS, and stimulated with ovalbumin (500 mg͞ml) for 56 h. APC activity was assessed by incorporation of [ 3 H]thymidine (added at 0.5 Ci per well for the last 18 h; 1 Ci ϭ 37 GBq). MHCII expression was detected by fluorescenceactivated cell sorting (FACS) by using phycoerythrin (PE)-conjugated anti I-A͞E Ab and FITC-conjugated anti-CD11b, CD11c, and CD19 Abs. All fluorochrome-conjugated Abs were provided by BD PharMingen (San Diego). In all flow cytometry experiments, acquisition and analysis were performed with FACS Calibur and CELLQUEST PRO software (BD Biosciences, San Jose, CA). M were stimulated with recombinant murine IFN-␥ (300 units͞ml).
7-amino-actinomycin D (7-AAD), according to the manufacturer's instructions. For FACS analysis, gated CD3ϩ cells were plotted for BrdUrd incorporation and total DNA content (7-AAD). T cell activation was measured by FACS in unfractionated BM and spleen cells stained with FITC-anti CD3 Ab and PE-anti CD25 or CD69 Abs (PharMingen). Activation and stress-induced apoptosis was analyzed by FACS as follows: purified CD4 ϩ cells were either activated with phorbol-12-myristate-13-acetate and ionomycin (both at 10 ng͞ml, Sigma) or irradiated (3,000 ␥-rad), and stained with FITCAnnexin V (PharMingen) and propidium iodide (PI). Annexin Vϩ, PIϪ cells were counted as apoptotic. FasL expression was detected by FACS using conjugated Abs recognizing FasL (MFL3, PharMingen). Reverse Transcriptase Real-Time PCR. Total cytoplasmic RNA preparation and reverse transcription were conducted as described (11) . Samples were analyzed by real-time PCR using a GeneAmp 5700 system (Applied Biosystems, Foster City, CA) and the following primers for CIITA: forward, 5Ј-AGGTTGTCAGT-GACTGCAGGC-3Ј; reverse, 5Ј-GCACAGCGACCACCT-GTGT-3Ј. Beta-tubulin served as the normalizing control (forward, 5Ј-GGAGAGCTGTGATTGCCTGC-3Ј; reverse, 5Ј-CCACCCAGTGAGTGGGTCAG-3Ј). The reaction was carried out in a final volume of 50 l containing 25 l of 0SYBR Green master mix (P͞N 4304886, PE Biosystems), 20 l of primers, and 5 l of cDNA, for 40 cycles. Each cycle consisted of 15 sec at 95°C and 1 min at 60°C. Analysis was performed by the ⌬⌬Ct method (PE Biosystems). Ct (cycle threshold) indicates the first PCR cycle at which an increase in reporter fluorescence above baseline can be detected. Fold change in mRNA is calculated as 2 Ϫ⌬⌬CT . ⌬⌬CT ϭ (Ct CIITA:ovx Ϫ Ct tubulin:ovx ) Ϫ (Ct CIITA:sham Ϫ Ct tubulin:sham ), where subscripts refer to mRNA amplified (CIITA or ␤-tubulin) and group of study (sham or ovx).
Bone Mineral Density (BMD) Measurements and Bone Histology.
Femoral BMD was determined in vivo at baseline and 2 and 4 weeks after surgery by using a PIXImus2 scanner (Lunar, Madison, WI). Data points represent average of both femurs for each mouse. The short-term reproducibility of this technique was 1.7%. For bone histology, left tibiae were excised, fixed in 10% formalin, decalcified, dehydrated, paraffin-embedded, sectioned, and stained with hematoxylin and for tartrate-resistant acid phosphatase activity, as described (8 
Results

Ovx Increases T Cell Activation and Lifespan of Activated T Cells.
In vivo BrdUrd incorporation studies conducted to determine how estrogen deficiency up-regulates BM T cell number revealed that ovx increases proliferation and decreases apoptosis of T cells (Fig. 1a) , two mechanisms that may be responsible for the T cell expansion induced by estrogen withdrawal. T cell proliferation is typically induced by activation. FACS analysis of the activation markers CD25 and CD69 showed that ovx increases the frequency of active T cells in the BM Ϸ2-fold (Fig. 1b) , suggesting that increased proliferation is activation-dependent.
Because Ag presentation by APC is key in the regulation of T cell activation, we examined the effect of ovx on different APC lineages. Ovx increases Ϸ2-fold APC activity of spleen cells, a source of MHCIIϩ professional APCs of multiple lineages, as assessed by proliferation of target T cells (Fig. 1c) . Analysis of subpopulations of APCs revealed that ovx specifically increases APC activity of M, but not that of DC and B cells. FACS analysis of MHCII expression, that confers and modulates APC activity (12) , revealed that ovx increases the frequency of MHCII-expressing M by Ͼ2-fold (Fig. 1d, time 0) . Furthermore, ovx increases MHCII induction by the physiological stimulant IFN-␥ in M (Fig. 1d) . In contrast, ovx has no effect on MHCII expression in B cells and DC (data not shown). Together, these findings indicate that ovx enhances activationinduced T cell proliferation by increasing M APC activity through augmented MHCII expression.
We then investigated how ovx down-regulates T cell apoptosis, a phenomenon that follows T cell activation and contributes to regulate the duration of the immune response. Lifespan of activated T cells is limited by apoptosis induced by membrane bound FasL, expressed by T cells in response to activation, through a mechanism mediated by the nuclear factor of activated T cells (NFAT). This apoptotic program is referred to as activation-induced cell death (AICD) (13) . Stress such as ␥-irradiation also induces FasL expression and apoptosis in T cells through a mechanism independent of NFAT (14) . We found that ovx markedly decreases AICD, but not stress-induced apoptosis (Fig. 1e ). In accordance with this observation, we found that ovx represses the expression of FasL induced by activation, but not that induced by irradiation (Fig. 1f ) , suggesting that ovx specifically blunts AICD by suppressing the activation-induced expression of FasL.
Altogether, these observations suggest that estrogen deficiency enhances T cell activation by potentiating APC activity in M, while extending the lifespan of active T cells by suppressing AICD. These alterations result in the expansion of the pool of active, TNF-producing T cells in the bone marrow, leading to chronic stimulation of osteoclast formation and bone loss. According to this hypothesis, the T cell expansion and the bone loss that follow ovx are dependent on T cell activation by APC.
APC Activity Is Required for Ovx-Induced T Cell Expansion and Bone
Loss. To determine whether the increased T cell proliferation and lifespan induced by ovx require APC-T cell interaction in vivo, we used DO11.10 mice, a strain characterized by impaired MHCII-T cell receptor (TCR) interaction, caused by the presence of a single TCR specificity toward the foreign Ag chicken albumin (ovalbumin) (15) . In DO11.10 mice, ovx fails to increase T cell proliferation and lifespan ( Table 1) . As a result, in these mice, ovx fails to increase the pool of TNF-producing T cells. Injection of ovalbumin in sham DO11.10 mice leads to an increase of both T cell proliferation and AICD, attributable to restoration of APC-T cell interaction, which results in a small (Ϸ0.5-fold) increase in the number of TNF producing T cells. In contrast, ovalbumin treatment restores the capacity of ovx to expand the pool of TNF-producing T cells by Ϸ3-fold by further increasing proliferation and by blunting T cell apoptosis. These data demonstrate that APC activity is critical in the process by which ovx increases T cell proliferation and lifespan, leading to increased T cell number.
To assess the relevance in vivo of APC-T cell interaction in ovx-induced bone loss, BMD was measured in vivo in DO11.10 mice and WT controls of identical genetic background before surgery and 2 and 4 weeks after either ovx or sham operation. In WT mice, ovx but not sham operation induced rapid bone loss (ovx: Ϫ7.7 Ϯ 1.4%, P Ͻ 0.05; sham ϩ2.64 Ϯ 0.8%, P ϭ not significant, compared with baseline). Sham and ovx DO11.10 mice sustained an equal, small bone loss during the first 2 weeks, presumably representing a sex steroid-independent response to surgical stress (Fig. 1g) , followed by return to baseline at 4 weeks from surgery. Thus, DO11.10 mice are protected against ovxinduced bone loss. In sham DO11.10 mice, treatment with ovalbumin was followed by a significant bone loss, attributable to the immune reaction to the Ag in the context of unstimulated APC activity (15) . In ovx DO11.10 mice, treatment with ovalbumin caused a significantly larger bone loss reflecting the cumulative effects of Ag stimulation and ovx-induced increased APC activity. Thus, in parallel with T cell expansion, treatment with ovalbumin restores the ability of ovx to induce bone loss in DO11.10 mice. Together, these findings demonstrate that APCinduced T cell activation is critical in the process by which ovx increases T cell number, and ultimately leads to bone loss.
Ovx Increases CIITA in APCs and T Cells Through Augmented IFN-␥. We then investigated how ovx increases APC activity and decreases AICD. CIITA is the master regulator of MHCII expression and APC activity (12) . Furthermore, CIITA expression in T cells prevents activation-induced FasL expression and apoptosis in vitro (16) and in vivo (17) . Thus, increased CIITA levels in M and T cells could mediate both the stimulatory effect on APC activity and the inhibitory effect on AICD induced by ovx. Indeed, reverse transcriptase real-time PCR analysis revealed 3-fold higher CIITA transcript levels in M and 2-fold higher levels in T cells from ovx mice, as compared with sham-operated controls (Fig. 2a) (19) . FACS analysis demonstrated that ovx enhances IFN-␥ production by T H cells in the BM, and also in secondary lymphoid organs, such as lymph nodes (Fig. 2b) and spleen (not shown). No effect of ovx on IFN-␥ production by natural killer (NK) cells, another potential source of this cytokine (20) , was detected by FACS (not shown). Thus, ovx specifically up-regulates T H 1 IFN-␥ production in vivo, despite reports that estrogen exerts a direct stimulatory effect on IFN-␥ gene expression in vitro (21) .
Measurements by ELISA confirmed that purified, unstimulated T H cells derived from ovx mice secrete detectable amounts of IFN-␥, whereas IFN-␥ is undetectable in culture supernatants of T H cells from sham controls (Fig. 2c) . IFN-␥ production by T H 1 cells is induced by either a cyclosporin A-sensitive TCRdependent mechanism, mediated by T cell activation, or by the cytokines IL-12 and IL-18 through activation of the mitogenactivated protein kinase p38 (19, 22) . Increased production of IFN-␥ by T H cells from ovx mice is suppressed by in vitro treatment with the selective p38 inhibitor SB203580, but not by the activation inhibitor cyclosporin A, suggesting that increased IFN-␥ production by T H cells in ovx mice is cytokine-driven.
The expression of IL-12 and IL-18 genes in M is induced by NF-B and AP-1 (23, 24) , nuclear proteins whose transcriptional activity is directly repressed by estrogen in M (25) (26) (27) . Unstimulated M, such as those from estrogen-replete mice, are known to express low or undetectable levels of NFkB and AP-1 (26, 28) . In keeping with these observations, we found that sham M express undetectable levels of IL-12 and IL-18. Furthermore, ovx increases secretion of IL-12 and IL-18 by BM M, whereas in vitro treatment with 17␤ estradiol represses it (Fig.  2d) . Thus, one mechanism by which ovx may increase CIITA expression is stimulation of IFN-␥ secretion via enhanced M production of the IFN-␥-inducing cytokines IL-12 and IL-18. (Fig. 3a) . Furthermore, ovx fails to suppress AICD in T cells derived from IFN-␥R Ϫ/Ϫ mice (Fig. 3b) . The inability of ovx to increase T cell proliferation and to decrease T cell apoptosis in IFN-␥R Ϫ/Ϫ mice was confirmed in vivo by BrdUrd incorporation analysis (Table 2) . Importantly, ovx of IFN-␥R Ϫ/Ϫ mice, but not of WT littermates, fails to increase the number of BM T cells and TNF-producing T cells in vivo, as assessed by FACS (Table 2) , and T cell TNF and IFN-␥ production in vitro, as assessed by ELISA (Fig. 3 c and d) . To determine whether IFN-␥ signaling mediates ovx-induced bone loss, BMD was measured in vivo in IFN-␥R Ϫ/Ϫ mice and WT controls before surgery and 2 and 4 weeks after either ovx or sham operation. Before surgery, BMD was identical in WT and null mice (data not shown), demonstrating that IFN-␥ signaling plays no role in skeletal development. At 4 weeks from ovx, BMD was significantly lower (Fig. 3e) than at baseline in WT mice (Ϫ8.0%), but not in IFN-␥R Ϫ/Ϫ mice (Ϫ2.6%). Histological analysis of long bones confirmed that the loss of trabeculae induced by ovx in WT mice is absent in IFN-␥R Ϫ/Ϫ mice (Fig. 3f ) . Together, our in vivo studies demonstrate that ovx causes T cell expansion and bone loss through APC-induced T cell activation and IFN-␥ signaling, via induction of the critical mediator CIITA.
IFN-␥R
Discussion
This study confirms that ovx-induced bone loss depends on the ability of estrogen deficiency to expand the number of TNF producing T cells. Furthermore, the data demonstrate that in vivo estrogen deficiency causes T cell expansion by enhancing T cell proliferation and lifespan. Both phenomena result from IFN-␥-mediated induction of CIITA in M and T cells. Increased CIITA expression leads to augmented Ag presentation by M, enhanced T cell activation, and increased activationdependent proliferation and lifespan of active T cells (Fig. 4 , which is published as supporting information on the PNAS web site, www.pnas.org).
A previously unknown, multifaceted role of IFN-␥ as regulator of bone homeostasis is disclosed. IFN-␥ is known to exert a direct anti-osteoclastogenic activity in vitro and to mitigate infectioninduced bone loss by inhibiting RANKL-induced osteoclastogenesis (29, 30) . Surprisingly, our findings reveal that in conditions of estrogen deficiency, IFN-␥-driven induction of CIITA leads to increased APC activity, T cell proliferation, and lifespan, events that ultimately lead to expansion of the T cell pool, enhanced T cell TNF production, and TNF-induced bone loss in vivo (4, 6, 7). Thus, despite its bone-sparing effects in some conditions, such as infection-induced bone loss, IFN-␥ is a critical enhancer of the bone loss induced by estrogen deficiency.
As to the mechanism of CIITA induction in ovx mice, our findings demonstrate the essential role of cytokine driven stimulation of IFN-␥ production and signaling. Importantly, because CIITA expression in T cells stimulates IFN-␥ production (18) , and IFN-␥ stimulates both its own inducers, IL-18 and IL-12, and IL-12 receptor expression (19, 24) , ovx triggers an amplification loop leading to a further increase in the level of IFN-␥ and the resulting induction of CIITA. The observation that ovx fails to increase IFN-␥ levels in IFN-␥R Ϫ/Ϫ mice confirms that increased IFN-␥ results primarily from IFN-␥-induced events such as IL-12 and IL-18 signaling, and CIITA expression (19, 24 ).
An increased responsiveness of CIITA to IFN-␥, disclosed by the higher MHCII expression in ovx than in sham M in response to IFN-␥, may contribute to increase CIITA levels in conditions of estrogen deficiency. Such increased responsiveness of ovx M to IFN-␥ is likely to be related to a priming effect induced by the high bone marrow level of IFN-␥ characteristic of ovx mice. Indeed, such phenomenon can be duplicated in vitro by the prolonged stimulation of sham M with the level of IFN-␥ measured in the bone marrow of ovx mice (data not shown).
The results of this study and of previous reports pointing to a causal role of TNF in ovx-induced bone loss are not in contrast with published evidence demonstrating the relevance of other estrogenregulated cytokines such as IL-1, IL-6, macrophage colonystimulating factor, and OPG (5). For example, the report that ovx fails to induce bone loss in TNF Ϫ/Ϫ mice (7) is not in conflict with studies demonstrating that mice lacking IL-6 (31) or IL-1R (32) are also protected against ovx induced bone loss. Cytokines are, in fact, under reciprocal control and organized in a cascade fashion. Thus, blockade of either upstream or downstream factors of the same cascade is effective in preventing bone loss in ovx mice. Furthermore, cytokines are recognized for their synergistic interactions. Thus, the neutralization of a single factor may achieve the same Ovx fails to increase T cell proliferation (cells in S phase), to decrease T cell apoptosis (cells in sub-G0͞G1 phase), and to increase BM T cells in DO11.10 mice (mean Ϯ SEM). *P Ͻ 0.05 as compared to untreated shams.
† P Ͻ 0.05 as compared to ovalbumin-treated shams.
effect as the neutralization of the sister cytokine or both factors. Examples are the well defined synergies between IL-1 and TNF (33) , and TNF and RANKL (4).
The current study provides evidence a novel regulatory link between the immune system and bone homeostasis, and contributes to elucidate the immune targets of estrogen deficiency. Interestingly, although our findings demonstrate that estrogen represses T H 1 activity and T cell production of the key inflammatory cytokine TNF, previous reports have shown immunostimulatory effects of estrogen (34) . These apparently conflicting observations underscore the complex effects of sex steroids on immunity. This complexity is caused by the effects of estrogen on other immunoregulatory hormones such as prolactin and progesterone (35) , the ability to regulate both pro-and antiinflammatory cytokines, and the capacity to exert relevant extraimmunological effects. Our findings are in accordance with clinical observations suggesting that in general estrogen stimu- lates T H 2 cytokine production and the humoral immune response, whereas it represses T H 1 behavior and cell-mediated immunity (5, (34) (35) (36) . In keeping with this hypothesis, rheumatoid arthritis and multiple sclerosis, cell-mediated T H 1-dependent autoimmune diseases, are relieved during pregnancy and are exacerbated in postpartum, whereas the opposite relationship is observed in systemic lupus erythematosus, an immune complex-mediated autoimmune disease (5, (37) (38) (39) .
In conclusion, not only may our findings contribute to explain why bone loss is commonly associated with inflammation and infection (40, 41) , but, should these findings be confirmed in humans, postmenopausal osteoporosis could be regarded as a disease stemming from an inappropriate immune response, triggered by estrogen deficiency. Thus, recognition of the immune targets of estrogen in vivo may lead to identification of new therapeutic interventions not only for osteoporosis, but also for autoimmune and inflammatory conditions. This study was supported in part by National Institutes of Health Grants AR41412, AR49659, and AG13534, the Pharmacia͞Washington University Grant Program, the Eastern Missouri Chapter of the Arthritis Foundation, and the Lilly Center for Women's Health. Ovx fails to increase T cell proliferation (cells in S phase), to decrease T cell apoptosis (cells in sub-G0͞G1 phase), and to increase BM T cells in IFN␥R Ϫ/Ϫ mice (mean Ϯ SEM). *P Ͻ 0.05 as compared to all other groups.
